Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 9/2017

01-09-2017 | Retinal Disorders

Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study

Authors: Masoud Soheilian, Saeed Karimi, Talieh Montahae, Homayoun Nikkhah, Seyed Aliasghar Mosavi

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 9/2017

Login to get access

Abstract

Purpose

To investigate the effects of intravitreal injection of bevacizumab (IVB) with or without anterior chamber paracentesis on intraocular pressure (IOP) and peripapillary retinal nerve fiber layer (PRNFL) thickness.

Methods

In this prospective randomized clinical trial, 90 eyes with center involving diabetic macular edema or wet type age-related macular degeneration (AMD) were randomly assigned to receive IVB either without (group A) or with (group B) anterior chamber paracentesis. IOP was measured before and within 2 min, 30 min, 24 hours and 3 months after injections. Peripapillary spectral-domain optical coherence tomography (SD-OCT) was performed before and 3 months after injections.

Results

Mean IOP changes 2 minutes, 30 minutes, 24 hours, and 3 months after injections were 26.4 ± 5.7 mmHg (P < 0.001), 6.5 ± 6.3 mmHg (P < 0.001), 0.2 ± 2.9 mmHg (P > 0.99) and 0.5 ± 2.4 mmHg (P > 0.99) in group A and −1.3 ± 2.4 mmHg (P < 0.001), −3.2 ± 1.8 mmHg (P < 0.001), −3.1 ± 1.8 mmHg (P < 0.001) and −1.8 ± 2.2 mmHg (P < 0.001) in group B, respectively Mean baseline average PRNFL thickness was 85.3±5.6 μm and 85.6 ± 5 μm in groups A and B respectively. Mean PRNFL thickness changes after 3 month was −2 ± 2 μm (P < 0.001) in group A and 0 ± 2 μm (P = 0.101) in group B. Mean PRNFL thickness in group A decreased more than group B (P < 0.001).

Conclusion

Conventional method of IVB injection was associated with acute IOP rise and significant PRNFL loss 3 months after injection. Anterior chamber paracentesis prevents acute IOP rise and PRNFL loss.
Literature
1.
Schlingemann RO, Witmer AN (2009) Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 175:253–267CrossRefPubMed
2.
Iliev ME, Domig D, Wolf-Schnurrbursch U et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. A J Ophthalmol 142:1054–1056CrossRef
3.
Horsley MB, Mandava N, Maycotte MA, Kahook MY (2010) Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol 150:558–561CrossRefPubMed
4.
Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N (2009) Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 40:293–295CrossRefPubMed
5.
Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 23:181–185CrossRefPubMed
6.
Falkenstein IA, Cheng L, Freeman WR (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 27:1044–1047CrossRefPubMed
7.
Frenkel RE, Mani L, Toler AR et al (2007) Intraocular pressure effects of pegaptanib (Macugen) injection in patients with and without glaucoma. Am J Ophthalmol 143:1034–1035CrossRefPubMed
8.
Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105–110CrossRefPubMed
9.
Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 95:1111–1114CrossRefPubMed
10.
Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008) Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246:955–958CrossRefPubMed
11.
Choi DY, Ortube MC, McCannel CA et al (2011) Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 31:1028–1035CrossRefPubMed
12.
Hoang QV, Mendonca LS, Della Torre KE et al (2012) Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 119:321–326CrossRefPubMed
13.
Mathalone N, Arodi-Golan A, Sar S et al (2012) Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 250:1435–1440CrossRefPubMed
14.
Seth RK, Salim S, Shields MB, Adelman RA (2009) Assessment of optic nerve cup–disc ratio changes in patients receiving multiple intravitreal injections. Retina 29:956–959CrossRefPubMed
15.
Knip MM, Valimaki J (2012) Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 90:254–258CrossRefPubMed
16.
Green K, Harman D, Cheeks L (1986) The interrelationship between intraocular pressure and Honan intraocular pressure reducer pressure. Curr Eye Res 5:621–624CrossRefPubMed
17.
Martel JN, Ying H, Shan C (2011) Severe intraocular pressure fluctuation after intravitreal anti-vascular endothelial growth factor injection. Ophthalmic Surgery, Lasers and Imaging 42:100–102
18.
Goktas A, Goktas S, Atas M et al (2013) Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure. Cutan Ocul Toxicol 32:23–26CrossRefPubMed
19.
Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and schwann cell proliferation in the peripheral nervous system. J Neurosci 19:5731–5740PubMed
20.
Fortune B, Yang H, Strouthidis NG, Cull GA, Grim JL, Downs JC (2009) The Effect of acute intraocular pressure elevation on prepapillary retinal thickness, retinal nerve fiber layer thickness and Retardance. Invest Ophthalmol Vis Sci 50:4719–4726CrossRefPubMedPubMedCentral
21.
Liu X, Li M, Zhong Y, Xiao H, Huang J, Mao Z (2011) The damage patterns of retinal nerve fiber layer in acute and chronic intraocular pressure elevation in primary angle closure glaucoma. Eye Science 26:154–160PubMed
22.
Martinez-de Ia Casa JM, Ruiz-Calvo AC, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzales C, Donate-Lopes J (2012) Retinal nerve fiber layer thickness changes in patients with age- related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218CrossRef
23.
Frencel MP, Haji SA, Frenkel RE (2010) Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 128:1523–1527CrossRef
24.
Zangwill L, Berry CA, Garden VS, Weinreb RN (1997) Reproducibility of retardation measurements with the nerve fibre analyzer II. J Glaucoma 6:384–389CrossRefPubMed
25.
Quigley HA, Addicks EM, Green WR (1982) Optic nerve damage in human glaucoma III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema and toxic neuropathy. Arch Ophthalmol 100:135–146CrossRefPubMed
26.
Skaf M, Bernardes AB, Cardillo JA, Costa RA, Melo LA, Castro JC, Varma R (2006) Retinal nerve fibre layer thickness profile in normal eyes using third-generation OCT. Eye (Lond) 20:431–439CrossRef
27.
Menke MN, Knecht P, Sturm V, Dabov S, Funk J (2008) Reproducibility of nerve fiber layer thickness measurements using 3D Fourier-domain OCT. Invest Ophthalmol Vis Sci 49:5386–5391CrossRefPubMed
28.
Liu X, Li M, Zhong YM, Xiao H, Huang JJ, Kong XY (2010) Damage patterns of retinal nerve fiber layer in acute and chronic intraocular pressure elevation in primary angle closure glaucoma. Int J Ophthalmol 3:152–157PubMedPubMedCentral
29.
Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS (2007) Short-term intraocular pressure trends after intravitreal triamcinolone injection. Am J Ophthalmol 143:365–367CrossRefPubMed
30.
Hayreh SS (1969) Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and edema of the optic disc. Br J Ophthalmol 53:721–748CrossRefPubMedPubMedCentral
31.
Anderson DR, Hendrickson A (1974) Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthalmol 13:771–783PubMed
32.
Quigley H, Anderson DR (1976) The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. Invest Ophthalmol 15:606–616PubMed
33.
Knox DL, Eagle RC Jr, Green WR (2007) Optic nerve hydropic axonal degeneration and blocked retrograde axoplasmic transport: histopathologic features in human high-pressure secondary glaucoma. Arch Ophthalmol 125:347–353CrossRefPubMed
34.
Harprasad SM, Shah GK, Blinder KJ (2006) Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 141:200–201CrossRef
35.
Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Lyer MN, Carvounis PE (2006) Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 113:1174–1178CrossRefPubMed
36.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113:992–1001CrossRef
37.
Metadata
Title
Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study
Authors
Masoud Soheilian
Saeed Karimi
Talieh Montahae
Homayoun Nikkhah
Seyed Aliasghar Mosavi
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 9/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3702-1

Other articles of this Issue 9/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 9/2017 Go to the issue

Miscellaneous

The clinical outcomes of surgical management of anterior chamber migration of a dexamethasone implant (Ozurdex®)

Retinal Disorders

Paravascular inner retinal abnormalities in healthy eyes

Glaucoma

Limbal rebound tonometry: clinical comparisons and applications

Letter to the Editor (by invitation)

Encouraging results of 25G+ minimally invasive vitrectomy surgery for diabetic tractional retinal detachment- reply

Retinal Disorders

Repeatability of ganglion cell-inner plexiform layer thickness measurements using spectral-domain OCT in branch retinal vein occlusion

Retinal Disorders

The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy